Brightangeltherapeutics
Toronto, CA · 1 known investors
Bright Angel Therapeutics develops novel small molecule therapeutics for treating drug-resistant and life-threatening fungal infections using computational drug discovery and proprietary fungal-selective inhibitor technologies. The company is a pre-clinical biotechnology firm targeting invasive fungal infections caused by resistant species including Candida, Cryptococcus, and Aspergillus.
BiotechDeep TechMedical Devices